Baseline multi‐omics signatures could predict therapeutic response to neoadjuvant anti‐PD‐1 immunochemotherapy in non‐small‐cell lung cancer

Documenti analoghi

• A multi‐omic biomarker signature in pre‐treatment rectal tumours stratifies patients with different pathological responses to neoadjuvant treatment
  di: Laura E. Kane, et al.
  Pubblicazione: (2025)
• Multi‐omics integration reveals a nonlinear signature that precedes progression of lung fibrosis
  di: Céline Pattaroni, et al.
  Pubblicazione: (2024)
• Multi‐omics predictive model based on clinical, radiomic and genomic features for predicting the response of limited‐stage small cell lung cancer to definitive chemoradiotherapy
  di: Li Li, et al.
  Pubblicazione: (2024)
• Integrative analyses of single‐cell and bulk RNA sequencing reveal tumour microenvironment features associated with neoadjuvant immunochemotherapy response in oesophageal squamous cell carcinoma
  di: Xianxian Wu, et al.
  Pubblicazione: (2025)
• Spatial omics accelerate the study of cancer‐associated fibroblasts in non‐small lung cancer
  di: Haozhen Liu, et al.
  Pubblicazione: (2024)